CO7091183A2 - Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos - Google Patents
Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricosInfo
- Publication number
- CO7091183A2 CO7091183A2 CO14224666A CO14224666A CO7091183A2 CO 7091183 A2 CO7091183 A2 CO 7091183A2 CO 14224666 A CO14224666 A CO 14224666A CO 14224666 A CO14224666 A CO 14224666A CO 7091183 A2 CO7091183 A2 CO 7091183A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- treatment
- sterilizer
- iloperidone
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610664P | 2012-03-14 | 2012-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7091183A2 true CO7091183A2 (es) | 2014-10-21 |
Family
ID=48407766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14224666A CO7091183A2 (es) | 2012-03-14 | 2014-10-09 | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10874659B2 (enExample) |
| EP (2) | EP3345603B1 (enExample) |
| JP (5) | JP2015510893A (enExample) |
| KR (2) | KR20170008327A (enExample) |
| CN (2) | CN108938632A (enExample) |
| AU (2) | AU2013232014B2 (enExample) |
| BR (1) | BR112014022687A8 (enExample) |
| CA (1) | CA2865845C (enExample) |
| CL (1) | CL2014002430A1 (enExample) |
| CO (1) | CO7091183A2 (enExample) |
| ES (2) | ES2773711T3 (enExample) |
| IL (1) | IL234412B (enExample) |
| IN (1) | IN2014DN08495A (enExample) |
| MX (1) | MX374067B (enExample) |
| RU (1) | RU2651710C2 (enExample) |
| WO (1) | WO2013138602A1 (enExample) |
| ZA (1) | ZA201406369B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2870498T3 (es) | 2015-02-17 | 2021-10-27 | Vanda Pharmaceuticals Inc | Iloperidona para el tratamiento de esquizofrenia |
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| JP2026504721A (ja) | 2022-12-19 | 2026-02-09 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン |
| WO2024249952A1 (en) * | 2023-06-02 | 2024-12-05 | Vanda Pharmaceuticals Inc. | Method of treatment with iloperidone |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| DK2305656T3 (da) | 2001-08-31 | 2013-02-11 | Novartis Ag | Optiske isomerer of en iloperidonmetabolit |
| PT1458888E (pt) | 2001-12-10 | 2011-06-01 | Novartis Ag | Métodos para tratar a psicose e a esquizofrenia baseados em polimorfismos no gene do cntf |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| AU2007253684A1 (en) * | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| EP2134873B1 (en) | 2007-03-29 | 2015-05-06 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| EP2198048A2 (en) | 2007-09-10 | 2010-06-23 | Vanda Pharmaceuticals Inc. | Prediction of qt prolongation based on snp genotype |
| WO2009036056A1 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
| CA2757723C (en) | 2009-04-06 | 2018-07-24 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
| HUE037724T2 (hu) | 2009-04-06 | 2018-09-28 | Vanda Pharmaceuticals Inc | Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre |
| EP2417266B1 (en) | 2009-04-06 | 2016-03-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| US9072742B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| CA2760474C (en) | 2009-05-15 | 2020-08-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
-
2013
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/ja active Pending
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/ko not_active Ceased
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/ru active
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/pt not_active Application Discontinuation
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 ES ES18152636T patent/ES2773711T3/es active Active
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/es active Active
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/zh active Pending
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/zh active Pending
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/ko not_active Ceased
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en not_active Ceased
- 2013-03-14 MX MX2014010989A patent/MX374067B/es active IP Right Grant
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/es unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/es unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/ja active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/ja active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/ja active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/ja active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
| BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
| MX2019003467A (es) | Formulaciones y metodos para la administracion vaginal de antiprogestinas. | |
| BR112014030678A2 (pt) | formas cristalinas de um modulador de receptor de androgênio | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| BR112014009851A8 (pt) | moduladores de receptor de nmda e usos dos mesmos | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
| UY33277A (es) | Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112016007016A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para tratamento sintomático do comprometimento cognitivo na demência, e, composição farmacêutica | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| MX376496B (es) | Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival. | |
| AR091706A1 (es) | Formulaciones de laquinimod sin agentes alcalinizantes | |
| PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| CO7091183A2 (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos | |
| DOP2015000071A (es) | Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación | |
| PY1330684A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina |